These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18565245)

  • 41. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis.
    Venetsanopoulou AI; Voulgari PV; Alamanos Y; Papadopoulos CG; Markatseli TE; Drosos AA
    Rheumatol Int; 2007 Aug; 27(10):935-9. PubMed ID: 17357804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
    Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
    Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
    J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.
    Stone MA; Inman RD; Wright JG; Maetzel A
    Arthritis Rheum; 2004 Jun; 51(3):316-20. PubMed ID: 15188313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis.
    Ariza-Ariza R; Hernández-Cruz B; Navarro-Sarabia F
    Arthritis Rheum; 2003 Aug; 49(4):483-7. PubMed ID: 12910553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J; van der Heijde D; Doyle MK; Han C; Deodhar A; Inman R; de Vlam K; Burmester GR; Van den Bosch F; Xu S; Visvanathan S; Rahman MU
    Arthritis Rheum; 2009 Aug; 61(8):1032-6. PubMed ID: 19644896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
    Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
    BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
    Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy.
    Jauregui E; Conner-Spady B; Russell AS; Maksymowych WP
    J Rheumatol; 2004 Dec; 31(12):2422-8. PubMed ID: 15570645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis.
    Kobayashi S; Yoshinari T
    Mod Rheumatol; 2017 Jan; 27(1):142-149. PubMed ID: 27299733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
    van der Heijde DM; Revicki DA; Gooch KL; Wong RL; Kupper H; Harnam N; Thompson C; Sieper J;
    Arthritis Res Ther; 2009; 11(4):R124. PubMed ID: 19686597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis].
    Huang F; Zhang J; Huang JL; Wu DH; Li ZG; Chen SL; Pan YF; Ma L; Chen S; Lü LJ; Yang ZM
    Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):741-5. PubMed ID: 21092442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs.
    Tenga G; Goëb V; Lequerré T; Bacquet-Deschryver H; Daragon A; Pouplin S; Lanfant-Weybel K; Le Loët X; Dieu B; Vittecoq O
    Joint Bone Spine; 2011 Jan; 78(1):50-5. PubMed ID: 20646950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study.
    Mörck B; Pullerits R; Geijer M; Bremell T; Forsblad-d'Elia H
    Mediators Inflamm; 2013; 2013():289845. PubMed ID: 24089587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.